TTF1 and adenosquamous carcinoma: In 2015, the WHO recommended that cases with coexpression of p63 and TTF1 (either within the same cells or in different tumor cells) be classified as ADC when TTF1 and p63 are positive in the same tumor cells and as adenosquamous carcinoma when these markers are positive in different populations of tumor cells.